Author:
Kockerols Camille C.B.,Geelen Inge G.P.,Levin Mark-David,Janssen Jeroen J.W.M.,Berna Beveloo H.,Dinmohamed Avinash G.,Hoogendoorn Mels,Cornelissen Jan J.,Westerweel Peter E.
Publisher
Ferrata Storti Foundation (Haematologica)
Reference17 articles.
1. Anastasi J, Feng J, Le Beau MM, Larson RA, Rowley JD, Vardiman JW. The relationship between secondary chromosomal abnormalities and blast transformation in chronic myelogenous leukemia. Leukemia. 1995; 9(4):628-633.
2. Marktel S, Marin D, Foot N. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica. 2003; 88(3):260-267.
3. Cortes JE, Talpaz M, Giles F. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood. 2003; 101(10):3794-3800.
4. Mitelman F, Levan G, Nilsson PG, Brandt L. Non-random karyotypic evolution in chronic myeloid leukemia. Int J Cancer. 1976; 18(1):24-30.
5. Wang W, Cortes JE, Tang G. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood. 2016; 127(22):2742-2750.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献